Hemophilia Treatment Market is estimated to be US$ 22.41 Billion in 2030 at a CAGR 6.1% during the forecast period

 




Hemophilia Treatment Market accounted for US$ 12.45 billion in 2020 and is estimated to be US$ 22.41 billion by 2030 and is anticipated to register a CAGR of 6.1%. Hemophilia is an inherited genetic disorder which disables the body\'s ability to make blood clots, a very important process needed to stop bleeding. Hence, Hemophilia leads to uncontrolled bleeding after the injury and can event lead to death.  The main type of hemophilia are hemophilia A, and hemophilia B, and hemophilia A occurs due to deficiency of clotting factor VIII and hemophilia B, occurs deficiency of clotting factor IX. Hemophilia is generally treated with genetically engineered clotting factor medicines which prevent and treat prolonged bleeding. According to the Centers of Disease Control and Prevention, Hemophilia A affects 1 in 5,000 male births and around 400 babies are born with hemophilia A each year. According to the same source currently, the number of people with hemophilia in the U.S is estimated to be about 20,000.

The report " Global Hemophilia Treatment Market, By Product (Recombinant coagulation factor concentrates, Plasma derived coagulation factor concentrates, Antifibrinolytic agents, and Desmopressin), By Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C) By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospitals, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030”

Key Highlights:

·         In 2020, Novo Nordisk has announced the launch of ESPEROCT, the company’s long-acting recombinant factor VIII product for the prevention and treatment of bleeding in individuals with hemophilia A. The new therapy is specifically indicated for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment, control of bleeding episodes and perioperative management of bleeding.

·         In 2020, The U.S. Food and Drug Administration approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies). Sevenfact contains an active ingredient expressed in genetically engineered rabbits.

Analyst View:

Key players in the market are focusing on gaining approval of its novel hemophilia treatment drugs in key regions such as Europe and Asia-Pacific. Approval of such drugs in key regions is expected to fuel market growth over forecast period. For instance, in August 2018, Bayer AG’s hemophilia treatment drug Jivi received approval in Europe and in September 2018, Jivi also received approval in Japan.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/2230

 

Key Market Insights from the report:

The Global Hemophilia Treatment Market accounted for US$ 12.45 billion in 2020 and is estimated to be US$ 22.41 billion by 2030 and is anticipated to register a CAGR of 6.1%. The global hemophilia treatment market has been segmented on the basis of drug type, disease type, distribution channel and region.

·         By Drug Type, the market is segmented into drug type, recombinant coagulation factor concentrates, plasma derived coagulation factor concentrates, antifibrinolytic agents, and desmopressi.

·         By Disease Type, the market is segmented into Hemophilia A, Hemophilia B, and Hemophilia C.

·         By Distribution Channel, the market is segmented into retail pharmacies, online pharmacies, and hospitals.

·         By Region, the Global Diabetic Neuropathy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape:

Key players operating in the global hemophilia treatment market includes Baxter International, Inc., Hospira, Inc., Baxalta, Novo Nordisk, BiogenInc., Pfizer, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc., Kedrion, Octapharma AG, Sanofi SA, Shire Plc., and Swedish Orphan Biovitrum AB.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

Prophecy Market Insights

  1 860 531 2701

Email- sales@prophecymarketinsights.com

 

Comments

Post a Comment

Popular posts from this blog

Patient Portal Market is estimated to be US$ 7862.01 billion by 2030 with a CAGR of 11.50% during the forecast period

Image
  Patient Portal Market  accounted for US$ 2643.21 million in 2020 and is estimated to be US$ 7862.01 million by 2030 and is anticipated to register a CAGR of 11.50%. The patients can share and view their health information and communicate remotely. These characteristics enables patients to look into various data points, such as diagnostic test results, medical history, and prescription information. Patient portal is one of the many tools that allow the healthcare payers and providers to arrive at outcomes, which are patient-centric. Rapid technological advancements in the digital space are rising the engagement level of patients in the entire healthcare ecosystem. Data points collected on a per-patient basis through patient portal can be used for performing pin-point diagnosis, designing better clinical trials, and helping in the elimination of administration of redundant therapies and drugs to individual patients. The report   "   Global Patient Portal Market, By P...
Read more

Knee Replacement Market is estimated to be 14.2 billion by 2029 with a CAGR of 4.3% during the forecasted period.

Image
  knee replacement market  accounted for 9.7 billion in 2020 and is estimated to be US$ 14.2 billion by 2029 and is anticipated to register a CAGR of 4.3%. The report " Global Knee Replacement Market, By Product ( Total Knee Replacement, Partial Knee Replacement, Kneecap Replacement, and Complex (or revision) Knee Replacement),  By End Users ( Hospitals, Orthopedic Centers, and Other ),  and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029” . Key Highlights: In March 2018, Smith and Nephew announced commercial release of bi-cruciate retaining Journey II XR total knee arthroplasty across the U.S. and Japan. The product launch was aimed at capturing large customer base with innovative product offering. In October 2018, Zimmer Biomet Holdings announced to collaborate with Apple to facilitate patient and surgeon connection during the knee and hip replacement procedures. Th...
Read more

Nuclear Medicine Market is estimated to be US$ 6.49 billion by 2030 with a CAGR of 4.30% during the forecast period

Image
  The Nuclear Medicine Market accounted for US$ 4.26 billion and is estimated to be US$ 6.49 billion by 2030 with a CAGR of 4.30% during the forecast period. Nuclear medicine may be a medicine involving the appliance of radioactive substances within the diagnosis and treatment of disease. Medicine imaging, during a sense, is "radiology done inside out" or "endoradiology" because it records radiation emitting from within the body instead of radiation that's generated by external sources like X-rays. Additionally, medicine scans differ from radiology, because the emphasis isn't on imaging anatomy, but on the function. For such reason, it's called a physiological imaging modality. Single photon emission computerized tomography (SPECT) and positron emission tomography (PET) scans are the 2 commonest imaging modalities in medicine.   The report "  Global Nuclear Medicine Market, By Diagnostics (Single Photon Emission, Computed Tomography (SPECT), an...
Read more